Nonthrombogenic approaches to cardiovascular bioengineering

Annual Review of Biomedical Engineering

Volumn 13, Issue , 2011, Pages 451-475

  Li, Song ^a   Henry, Jeffrey J D ^a  

^a University of California at Berkeley   (United States)

Author keywords

Antithrombogenic; Endothelial cell; Heart valve; Platelet; Stem cell; Stent; Thrombin; Vascular graft; Vascularized tissues

Indexed keywords

ANTITHROMBOGENIC; HEART VALVE; STENT; THROMBIN; VASCULAR GRAFTS; VASCULARIZED TISSUES;

GRAFTS; HISTOLOGY; STEM CELLS; TISSUE; TISSUE ENGINEERING;

ENDOTHELIAL CELLS;

ACETYLSALICYLIC ACID; ALBUMIN; BENZALKONIUM CHLORIDE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; CLOPIDOGREL; FIBRIN; FIBRINOGEN; FIBRINOLYTIC AGENT; GLYCOSAMINOGLYCAN; HEPARIN; HIRUDIN; MACROGOL; NITRIC OXIDE; PACLITAXEL; PHOSPHORYLCHOLINE; POLITEF; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYURETHAN; PROSTACYCLIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEOHEPARAN SULFATE; RAPAMYCIN; THROMBIN; THROMBOMODULIN; THROMBOXANE A2; TISSUE FACTOR PATHWAY INHIBITOR; VERY LATE ACTIVATION ANTIGEN 2; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD VESSEL GRAFT; BONE MARROW CELL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EQUIPMENT; CELL MIGRATION; CELL PROLIFERATION; CHEMICAL MODIFICATION; DACRON VASCULAR PROSTHESIS; ENDOTHELIUM CELL; FIBRINOLYSIS; HEART VALVE BIOPROSTHESIS; HEART VALVE REPLACEMENT; MESENCHYMAL STEM CELL; NONHUMAN; OXYGEN TRANSPORT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STEM CELL; STENT; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOGENESIS; THROMBOGENICITY; THROMBOSIS; TISSUE ENGINEERING;

ANTICOAGULANTS; BIOCOMPATIBLE MATERIALS; BIOENGINEERING; BIOPROSTHESIS; BLOOD VESSEL PROSTHESIS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CELL ADHESION; ENDOTHELIAL CELLS; HEART VALVE PROSTHESIS; HUMANS; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; PLATELET ADHESIVENESS; STEM CELLS; SURFACE PROPERTIES; THROMBOSIS; TISSUE ENGINEERING; VASCULAR GRAFTING;

EID: 79960501436     PISSN: 15239829     EISSN: 15454274     Source Type: Book Series    
DOI: 10.1146/annurev-bioeng-071910-124733     Document Type: Article

References (185)

1. Ross R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801-9 (Pubitemid 23132154)
2. Ross R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340:115-26
3. Kannan RY, Salacinski HJ, Sales K, Butler P, Seifalian AM. 2005. The roles of tissue engineering and vascularisation in the development of micro-vascular networks: a review. Biomaterials 26:1857-75
4. L'HeureuxN,Dusserre N, Marini A, Garrido S, de la Fuente L, McAllisterT. 2007. Technology insight: the evolution of tissue-engineered vascular grafts-from research to clinical practice. Nat. Clin. Pract. Cardiovasc. Med. 4:389-95 (Pubitemid 47023444)
5. LovettM, Lee K, Edwards A, Kaplan DL. 2009. Vascularization strategies for tissue engineering. Tissue Eng. Part B Rev. 15:353-70
6. Nerem RM, Seliktar D. 2001. Vascular tissue engineering. Annu. Rev. Biomed. Eng. 3:225-43 (Pubitemid 32928039)
7. Niklason LE, Langer RS. 1997. Advances in tissue engineering of blood vessels and other tissues. Transpl. Immunol. 5:303-6
8. Sacks MS, Schoen FJ, Mayer JE Jr. 2009. Bioengineering challenges for heart valve tissue engineering. Annu. Rev. Biomed. Eng. 11:289-313
9. Vesely I. 2005. Heart valve tissue engineering. Circ. Res. 97:743-55 (Pubitemid 41447124)
10. Veith FJ, Gupta SK, Ascer E, White-Flores S, Samson RH, et al. 1986. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. J. Vasc. Surg. 3:104-14 (Pubitemid 16186498)
11. Lytle B, Loop F, Cosgrove D, Ratliff N, Easley K, Taylor P. 1985. Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J. Thorac. Cardiovasc. Surg. 89:248-58 (Pubitemid 16248435)
12. Huynh T, Abraham G, Murray J, Brockbank K, Hagen P, Sullivan S. 1999. Remodeling of acellular collagen graft into a physiologically responsive neovessel. Nat. Biotechnol. 17:1083-86
13. Adili F, Balzer JO, Ritter R-G, Schmandra TC, Tenholt M, et al. 2004. Ruptured abdominal aortic aneurysm with aorto-caval fistula. J. Vasc. Surg. 40:582 (Pubitemid 39165042)
14. Ricco JB, Marchand C, Neau JP, Marchand E, Cau J, F́ebrer G. 2009. Prosthetic carotid bypass grafts for atherosclerotic lesions: a prospective study of 198 consecutive cases. Eur. J. Vasc. Endovasc. Surg. 37:272-78
15. Jensen LP, Lep̈antalo M, Fossdal JE, RøderOC, Jensen BS, et al. 2007. Dacron or PTFE for above-knee femoropopliteal bypass: a multicenter randomised study. Eur. J. Vasc. Endovasc. Surg. 34:44-49 (Pubitemid 46863199)
16. Tomizawa Y. 1995. Vascular prostheses for aortocoronary bypass grafting: a review. Artif. Organs 19:39-45
17. Parsons RE, Suggs WD, Veith FJ, Sanchez LA, Lyon RT, et al. 1996. Polytetrafluoroethylene bypasses to infrapopliteal arteries without cuffs or patches: a better option than amputation in patients without autologous vein. J. Vasc. Surg. 23:347-54; discussion 55-56
18. ChardRB, Johnson DC,NunnGR, Cartmill TB. 1987. Aorta-coronary bypass grafting with polytetrafluoroethylene conduits: early and late outcome in eight patients. J. Thorac. Cardiovasc. Surg. 94:132-34 (Pubitemid 17093918)
19. Sourgounis A, Lipiecki J, Lo TS, Hamon M. 2009. Coronary stents and chronic anticoagulation. Circulation 119:1682-88
20. DrachmanDE, Edelman ER, Seifert P, Groothuis AR, Bornstein DA, et al. 2000. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J. Am. Coll. Cardiol. 36:2325-32
21. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, et al. 2001. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104:473-79 (Pubitemid 32678280)
22. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, et al. 2002. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J.Med. 346:1773-80
23. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, et al. 2001. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103:192-95 (Pubitemid 32095401)
24. Suzuki T, KopiaG,Hayashi S, Bailey LR, Llanos G, et al. 2001. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104:1188-93
25. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, et al. 2004. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364:1519-21
26. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, et al. 2004. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 109:701-5 (Pubitemid 38222887)
27. Cannegieter S, Rosendaal F, Briet E. 1994. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 89:635-41 (Pubitemid 24056190)
28. Marchand M, Aupart M, Norton R, Goldsmith I, Pelletier L, et al. 2001. Fifteen-year experience with themitral Carpentier-Edwards PERIMOUNT pericardial bioprosthesis. Ann. Thorac. Surg. 71:S236-39 (Pubitemid 32436969)
29. Rahimtoola S. 2003. Choice of prosthetic heart valve for adult patients. J. Am. Coll. Cardiol. 41:893-904 (Pubitemid 36315528)
30. Chrobak KM, Potter DR, Tien J. 2006. Formation of perfused, functional microvascular tubes in vitro. Microvasc. Res. 71:185-96 (Pubitemid 43794856)
31. Kaihara S, Borenstein J, Koka R, Lalan S, Ochoa ER, et al. 2000. Silicon micromachining to tissue engineer branched vascular channels for liver fabrication. Tissue Eng. 6:105-17 (Pubitemid 30227167)
32. Mironov V, Boland T, Trusk T, Forgacs G, Markwald RR. 2003. Organ printing: computer-aided jet-based 3D tissue engineering. Trends Biotechnol. 21:157-61 (Pubitemid 36397983)
33. Ott HC, Clippinger B, Conrad C, Schuetz C, Pomerantseva I, et al. 2010. Regeneration and orthotopic transplantation of a bioartificial lung. Nat. Med. 16:927-33
34. Ott HC, Matthiesen TS, Goh SK, Black LD, Kren SM, et al. 2008. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat. Med. 14:213-21 (Pubitemid 351214548)
35. Petersen TH, Calle EA, Zhao L, Lee EJ, Gui L, et al. 2010. Tissue-engineered lungs for in vivo implantation. Science 329:538-41
36. Uygun BE, Soto-Gutierrez A, Yagi H, Izamis ML, Guzzardi MA, et al. 2010. Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. Nat. Med. 16:814-20
37. Chen X, Aledia AS,Ghajar CM, Griffith CK, Putnam AJ, et al. 2009. Prevascularization of a fibrin-based tissue construct accelerates the formation of functional anastomosis with host vasculature. Tissue Eng. Part A 15:1363-71
38. Ruggeri ZM. 1997. Mechanisms initiating platelet thrombus formation. Thromb. Haemost. 78:611-16 (Pubitemid 27289313)
39. Ruggeri ZM. 2000. Role of vonWillebrand factor in platelet thrombus formation. Ann. Med. 32(Suppl. 1):2-9 (Pubitemid 32115800)
40. Mackman N. 2008. Triggers, targets and treatments for thrombosis. Nature 451:914-18
41. McCarty OJT, Zhao Y, Andrew N, Machesky LM, Staunton D, et al. 2004. Evaluation of the role of platelet integrins in fibronectin-dependent spreading and adhesion. J. Thromb. Haemost. 2:1823-33
42. Bennett JS, Berger BW, Billings PC. 2009. The structure and function of platelet integrins. J. Thromb. Haemost. 7(Suppl. 1):200-5
43. Blockmans D, Deckmyn H, Vermylen J. 1995. Platelet actuation. Blood Rev. 9:143-56
44. Ruggeri ZM. 2009. Platelet adhesion under flow. Microcirculation 16:58-83
45. Gorbet MB, SeftonMV. 2004. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 25:5681-703 (Pubitemid 38624449)
46. DavieEW,Fujikawa K, KisielW.1991. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30:10363-70
47. Sherwood L. 2007. Human Physiology: From Cells to Systems. Belmont, CA: Brooks/Cole. 5th ed.
48. Furie B, Furie BC. 2008. Mechanisms of thrombus formation. N. Engl. J. Med. 359:938-49
49. Park K, Mao F, Park H. 1990. Morphological characterization of surface-induced platelet activation. Biomaterials 11:24-31 (Pubitemid 20088527)
50. Schmaier AH. 1997. Contact activation: a revision. Thromb. Haemost. 78:101-7 (Pubitemid 27289224)
51. Schmaier AH. 2000. Plasma kallikrein/kinin system: a revised hypothesis for its activation and its physiologic contributions. Curr. Opin. Hematol. 7:261-65 (Pubitemid 30637663)
52. Burman J. 1994. Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass. Lancet 344:1192-93
53. Wilcox JN, Smith KM, Schwartz SM,Gordon D. 1989. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Natl. Acad. Sci. USA 86:2839-43
54. Coughlin SR. 2000. Thrombin signaling and protease-activated receptors. Nature 407:258-64
55. Giesen PL, Rauch U, Bohrmann B, Kling D, Roqúe M, et al. 1999. Blood-borne tissue factor: another view of thrombosis. Proc. Natl. Acad. Sci. USA 96:2311-15
56. Michiels C. 2003. Endothelial cell functions. J. Cell. Physiol. 196:430-43 (Pubitemid 36927738)
57. Wu KK, Thiagarajan P. 1996. Role of endothelium in thrombosis and hemostasis. Annu. Rev. Med. 47:315-31 (Pubitemid 26138894)
58. van Hinsbergh VW. 2001. The endothelium: vascular control of haemostasis. Eur. J. Obstet. Gynecol. Reprod. Biol. 95:198-201 (Pubitemid 32297718)
59. Bernfield M, G̈otte M, Park PW, Reizes O, Fitzgerald ML, et al. 1999. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68:729-77 (Pubitemid 29449208)
60. Bernfield M, Kokenyesi R, KatoM,HinkesMT, Spring J, et al. 1992. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu. Rev. Cell Biol. 8:365-93 (Pubitemid 23001002)
61. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. 1996. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc. Natl. Acad. Sci. USA 93:10212-16 (Pubitemid 26314601)
62. Broze GJ. 1995. Tissue factor pathway inhibitor. Thromb. Haemost. 74:90-93
63. Hackeng TM, Maurissen LFA, Castoldi E, Rosing J. 2009. Regulation of TFPI function by protein S. J. Thromb. Haemost. (Suppl. 1):165-68
64. Hackeng TM, Seŕe KM, Tans G, Rosing J. 2006. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc. Natl. Acad. Sci. USA 103:3106-11
65. Best LC,Martin TJ, Russell RG, Preston FE. 1977. Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets. Nature 267:850-52 (Pubitemid 8110164)
66. de Graaf JC, Banga JD, Moncada S, Palmer RM, de Groot PG, Sixma JJ. 1992. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 85:2284-90
67. Radomski MW, Vallance P, Whitley G, Foxwell N, Moncada S. 1993. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc. Res. 27:1380-82
68. Knudsen HL, Frangos JA. 1997. Role of cytoskeleton in shear stress-induced endothelial nitric oxide production. Am. J. Physiol. 273:H347-55
69. Pearson JD, Carleton JS, Gordon JL. 1980. Metabolism of adenine nucleotides by ectoenzymes of vascular endothelial and smooth-muscle cells in culture. Biochem. J. 190:421-29 (Pubitemid 11245812)
70. Weinbaum S, Tarbell JM, Damiano ER. 2007. The structure and function of the endothelial glycocalyx layer. Annu. Rev. Biomed. Eng. 9:121-67 (Pubitemid 350246654)
71. Hashi CK, Zhu Y, Yang GY, Young WL, Hsiao BS, et al. 2007. Antithrombogenic property of bone marrow mesenchymal stem cells in nanofibrous vascular grafts. Proc. Natl. Acad. Sci. USA 104:11915-20 (Pubitemid 47185605)
72. Chien S. 2003. Molecular and mechanical bases of focal lipid accumulation in arterial wall. Prog. Biophys. Mol. Biol. 83:131-51 (Pubitemid 36821273)
73. Moon JJ, Matsumoto M, Patel S, Lee L, Guan JL, Li S. 2005. Role of cell surface heparan sulfate proteoglycans in endothelial cell migration and mechanotransduction. J. Cell. Physiol. 203:166-76 (Pubitemid 40328183)
74. Weinbaum S, Zhang X, Han Y, Vink H, Cowin SC. 2003. Mechanotransduction and flow across the endothelial glycocalyx. Proc. Natl. Acad. Sci. USA 100:7988-95
75. Florian JA, Kosky JR, Ainslie K, Pang Z, Dull RO, Tarbell JM. 2003. Heparan sulfate proteoglycan is a mechanosensor on endothelial cells. Circ. Res. 93:e136-42
76. Matsuno H, Kozawa O, Niwa M, Ueshima S, Matsuo O, et al. 1999. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury. Thromb. Haemost. 81:601-4 (Pubitemid 29178949)
77. Fay WP, Garg N, Sunkar M. 2007. Vascular functions of the plasminogen activation system. Arterioscler. Thromb. Vasc. Biol. 27:1231-37
78. Schneiderman J, Sawdey MS, Keton MR, Bordin GM, Bernstein EF, et al. 1992. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc. Natl. Acad. Sci. USA 89:6998-7002
79. Bajou K, Nöel A, Gerard RD,Masson V, Brunner N, et al. 1998. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4:923-28 (Pubitemid 28364031)
80. Fay WP. 2004. Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury. Trends Cardiovasc. Med. 14:196-202 (Pubitemid 38942828)
81. van Hinsbergh VW, van den Berg EA, Fiers W, Dooijewaard G. 1990. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood 75:1991-98
82. Ohshiro T, Kosaki G. 1980. Urokinase immobilized on medical polymeric materials: fundamental and clinical studies. Artif. Organs 4:58-64 (Pubitemid 10134980)
83. Watanabe S, Shimizu Y, Teramatsu T, Murachi T, Hino T. 1981. The in vitro and in vivo behavior of urokinase immobilized onto collagen-synthetic polymer composite material. J. Biomed. Mater. Res. 15:553-63 (Pubitemid 11125908)
84. Holmer E, Kurachi K, S̈oderstr ̈om G. 1981. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem. J. 193:395-400 (Pubitemid 11141360)
85. Gott VL, Whiffen JD, Dutton RC. 1963. Heparin bonding on colloidal graphite surfaces. Science 142:1297-98
86. Ritter EF, Fata MM, Rudner AM, Klitzman B. 1998. Heparin bonding increases patency of long microvascular prostheses. Plast. Reconstr. Surg. 101:142-46 (Pubitemid 28022931)
87. Walpoth BH, Rogulenko R, Tikhvinskaia E, Gogolewski S, Schaffner T, et al. 1998. Improvement of patency rate in heparin-coated small synthetic vascular grafts. Circulation 98:II319-23; discussion II324 (Pubitemid 28512206)
88. Park K, Shim HS, Dewanjee MK, Eigler NL. 2000. In vitro and in vivo studies of PEO-grafted bloodcontacting cardiovascular prostheses. J. Biomater. Sci. Polym. Ed. 11:1121-34
89. Tay S,Merrill E, Salzman E, Lindon J. 1989. Activity toward thrombin-antithrombin of heparin immobilized on two hydrogels. Biomaterials 10:11-15 (Pubitemid 19052584)
90. Nojiri C, Park KD, Grainger DW, Jacobs HA, Okano T, et al. 1990. In vivo nonthrombogenicity of heparin immobilized polymer surfaces. ASAIO Trans. 36:M168-72 (Pubitemid 20367011)
91. Larm O, Larsson R, Olsson P. 1983. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater.Med. Devices Artif. Organs 11:161-73 (Pubitemid 14168691)
92. Olsson P, Sanchez J, Mollnes TE, Riesenfeld J. 2000. On the blood compatibility of end-point immobilized heparin. J. Biomater. Sci. Polym. Ed. 11:1261-73
93. Hardhammar PA, van BeusekomHM, EmanuelssonHU, Hofma SH, Albertsson PA, et al. 1996. Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation 93:423-30 (Pubitemid 26043600)
94. Serruys PW, Emanuelsson H, van der GiessenW, Lunn AC, Kiemeney F, et al. 1996. Heparin-coated Palmaz-Schatz stents in human coronary arteries: early outcome of the Benestent-II Pilot Study. Circulation 93:412-22 (Pubitemid 26043599)
95. Grainger DW, Okano T, Kim SW, Castner DG, Ratner BD, et al. 1990. Poly(dimethylsiloxane)-poly(ethylene oxide)-heparin block copolymers. III: Surface and bulk compositional differences. J. Biomed. Mater. Res. 24:547-71 (Pubitemid 20269702)
96. Walluscheck KP, Bierkandt S, Brandt M, Cremer J. 2005. Infrainguinal ePTFE vascular graft with bioactive surface heparin bonding: first clinical results. J. Cardiovasc. Surg. 46:425-30 (Pubitemid 41582232)
97. Devine C, McCollum C. 2004. Heparin-bonded Dacron or polytetrafluoroethylene for femoropopliteal bypass: five-year results of a prospective randomized multicenter clinical trial. J. Vasc. Surg. 40:924-31 (Pubitemid 39535222)
98. FairbrotherWJ, Champe MA, Christinger HW, Keyt BA, Starovasnik MA. 1998. Solution structure of the heparin-binding domain of vascular endothelial growth factor. Structure 6:637-48 (Pubitemid 28258116)
99. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. 1999. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13:9-22 (Pubitemid 29038270)
100. Sakiyama-Elbert S. 2000. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J. Control. Release 65:389-402 (Pubitemid 30122941)
101. De Scheerder I,Wang K,Wilczek K,Meuleman D, Van Amsterdam R, et al. 1997. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. Circulation 95:1549-53
102. Goodwin SC, Yoon HC, Chen G, Abdel-Sayed P, Costantino MM, et al. 2003. Intense inflammatory reaction to heparin polymer coated intravascular Palmaz stents in porcine arteries compared to uncoated Palmaz stents. Cardiovasc. Interv. Radiol. 26:158-67 (Pubitemid 36919558)
103. Gr̈utter MG, Priestle JP, Rahuel J, Grossenbacher H, Bode W, et al. 1990. Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition. EMBO J. 9:2361-65
104. Schmitz T, Rothe M, Dodt J. 1991. Mechanism of the inhibition of α-thrombin by hirudin-derived fragments hirudin(1-47) and hirudin(45-65). Eur. J. Biochem. 195:251-56
105. Seifert B, Romaniuk P, Groth T. 1997. Covalent immobilization of hirudin improves the haemocompatibility of polylactide-polyglycolide in vitro. Biomaterials 18:1495-502 (Pubitemid 27496638)
106. Phaneuf MD, Berceli SA, Bide MJ, Quist WC, LoGerfo FW. 1997. Covalent linkage of recombinant hirudin to poly(ethylene terephthalate) (Dacron): creation of a novel antithrombin surface. Biomaterials 18:755-65 (Pubitemid 27197482)
107. Wyers MC, Phaneuf MD, Rzucidlo EM, Contreras MA, LoGerfo FW, Quist WC. 1999. In vivo assessment of a novel Dacron surface with covalently bound recombinant hirudin. Cardiovasc. Pathol. 8:153-59 (Pubitemid 29290830)
108. Lahann J, Pl ̈usterW, Klee D, Gattner H-G, Ḧocker H. 2001. Immobilization of the thrombin inhibitor r-hirudin conserving its biological activity. J. Mater. Sci. Mater. Med. 12:807-10 (Pubitemid 32996122)
109. Hashi CK, Derugin N, Janairo RRR, Lee R, Schultz D, et al. 2010. Antithrombogenic modification of small-diameter microfibrous vascular grafts. Arterioscler. Thromb. Vasc. Biol. 30:1621-27
110. Alt E, Haehnel I, Beilharz C, Prietzel K, Preter D, et al. 2000. Inhibition of neointima formation after experimental coronary artery stenting: a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost. Circulation 101:1453-58
111. Lahann J, Klee D, Pluester W, HoeckerH. 2001. Bioactive immobilization of r-hirudin on CVD-coated metallic implant devices. Biomaterials 22:817-26 (Pubitemid 32143795)
112. Di Nisio M, Middeldorp S, Buller HR. 2005. Direct thrombin inhibitors. N. Engl. J. Med. 353:1028-40
113. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. 1990. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29:7095-101 (Pubitemid 20241158)
114. Li W, Kaplan A, GrantG, Toole J, Leung L. 1994. A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation. Blood 83:677-82 (Pubitemid 24043727)
115. Pagano B, Martino L, Randazzo A, Giancola C. 2008. Stability and binding properties of a modified thrombin binding aptamer. Biophys. J. 94:562-69
116. Kishida A, Ueno Y, Fukudome N, Yashima E, Maruyama I, Akashi M. 1994. Immobilization of human thrombomodulin onto poly(ether urethane urea) for developing antithrombogenic blood-contacting materials. Biomaterials 15:848-52 (Pubitemid 24252004)
117. Tseng P-Y,Rele SS, SunX-L,Chaikof EL. 2006. Membrane-mimetic films containing thrombomodulin and heparin inhibit tissue factor-induced thrombin generation in a flow model. Biomaterials 27:2637-50
118. Kishida A, Akatsuka Y, YanagiM, Aikou T, Maruyama I, Akashi M. 1995. In vivo and ex vivo evaluation of the antithrombogenicity of human thrombomodulin immobilized biomaterials. ASAIO J. 41:M369-74
119. Li J, Singh MJ, Nelson PR, Hendricks GM, Itani M, et al. 2002. Immobilization of human thrombomodulin to expanded polytetrafluoroethylene. J. Surg. Res. 105:200-8 (Pubitemid 34765328)
120. Wong G, Li J-M, Hendricks G, Eslami MH, Rohrer MJ, Cutler BS. 2008. Inhibition of experimental neointimal hyperplasia by recombinant human thrombomodulin coated ePTFE stent grafts. J. Vasc. Surg. 47:608-15 (Pubitemid 351258276)
121. Sun LB, Utoh J, Moriyama S, Tagami H, OkamotoK,KitamuraN. 2001. Pretreatment of aDacron graft with tissue factor pathway inhibitor decreases thrombogenicity and neointimal thickness: a preliminary animal study. ASAIO J. 47:325-28 (Pubitemid 32655800)
122. Wang PG, Xian M, Tang X, Wu X, Wen Z, et al. 2002. Nitric oxide donors: chemical activities and biological applications. Chem. Rev. 102:1091-134 (Pubitemid 35377604)
123. Keefer LK, Saavedra JE. 2002. Nitrogen-based diazeniumdiolates: versatile nitric oxide-releasing compounds for biomedical research and potential clinical applications. J. Chem. Educ. 79:1427
124. Ignarro LJ, Napoli C, Loscalzo J. 2002. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ. Res. 90:21-28 (Pubitemid 34074604)
125. Smith DJ, Chakravarthy D, Pulfer S, Simmons ML, Hrabie JA, et al. 1996. Nitric oxide-releasing polymers containing the [N(O)NO]? group. J. Med. Chem. 39:1148-56
126. Jun H-W, Taite LJ, West JL. 2005. Nitric oxide-producing polyurethanes. Biomacromolecules 6:838-44 (Pubitemid 40467826)
127. GombotzWR, Wang GH, Horbett TA, Hoffman AS. 1991. Protein adsorption to poly(ethylene oxide) surfaces. J. Biomed. Mater. Res. 25:1547-62
128. Harder P, Grunze M, Dahint R, Whitesides GM, Laibinis PE. 1998. Molecular conformation in oligo(ethylene glycol)-terminated self-assembled monolayers on gold and silver surfaces determines their ability to resist protein adsorption. J. Phys. Chem. B 102:426-36 (Pubitemid 128581104)
129. Sofia S, Premnath V, Merrill E. 1998. Poly(ethylene oxide) grafted to silicon surfaces: grafting density and protein adsorption. Macromolecules 31:5059-70
130. Bernacca GM,GulbransenMJ, Wilkinson R,Wheatley DJ. 1998. In vitro blood compatibility of surfacemodified polyurethanes. Biomaterials 19:1151-65
131. Deible CR, Petrosko P, Johnson PC, Beckman EJ, Russell AJ, Wagner WR. 1998. Molecular barriers to biomaterial thrombosis by modification of surface proteins with polyethylene glycol. Biomaterials 19:1885-93
132. Han DK, Lee KB, Park KD, Kim CS, Jeong SY, et al. 1993. In vivo canine studies of a Sinkhole valve and vascular graft coated with biocompatible PU-PEO-SO3. ASAIO J. 39:M537-41
133. Nojiri C, Okano T, Jacobs HA, Park KD, Mohammad SF, et al. 1990. Blood compatibility of PEO grafted polyurethane and HEMA/styrene block copolymer surfaces. J. Biomed. Mater. Res. 24:1151-71
134. Hubbell J. 1993. Pharmacologic modification of materials. Cardiovasc. Pathol. 2(3, Suppl. 1):121-27
135. Kito H, Matsuda T. 1996. Biocompatible coatings for luminal and outer surfaces of small-caliber artificial grafts. J. Biomed. Mater. Res. 30:321-30 (Pubitemid 26071921)
136. Chuang TW, Masters KS. 2009. Regulation of polyurethane hemocompatibility and endothelialization by tethered hyaluronic acid oligosaccharides. Biomaterials 30:5341-51
137. Jordan SW, Faucher KM, Caves JM, Apkarian RP, Rele SS, et al. 2006. Fabrication of a phospholipid membrane-mimetic film on the luminal surface of an ePTFE vascular graft. Biomaterials 27:3473-81
138. Kaladhar K, Sharma CP. 2006. Cell mimetic lateral stabilization of outer cell mimetic bilayer on polymer surfaces by peptide bonding and their blood compatibility. J. Biomed. Mater. Res. A 79:23-35 (Pubitemid 44452851)
139. Lewis AL, Furze JD, Small S, Robertson JD, Higgins BJ, et al. 2002. Long-term stability of a coronary stent coating post-implantation. J. Biomed. Mater. Res. 63:699-705 (Pubitemid 35375415)
140. Atalar E, Haznedaroglu I, Aytemir K, Aksoyek S, Ovunc K, et al. 2001. Effects of stent coating on platelets and endothelial cells after intracoronary stent implantation. Clin. Cardiol. 24:159-64 (Pubitemid 32108626)
141. Chen C, Lumsden AB, Ofenloch JC, Noe B, Campbell EJ, et al. 1997. Phosphorylcholine coating of ePTFE grafts reduces neointimal hyperplasia in canine model. Ann. Vasc. Surg. 11:74-79 (Pubitemid 27164376)
142. Collingwood R, Gibson L, Sedlik S, Virmani R, Carter AJ. 2005. Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model. Catheter. Cardiovasc. Interv. 65:227-32 (Pubitemid 40791517)
143. Kuiper KK, Robinson KA, Chronos NA, Cui J, Palmer SJ, Nordrehaug JE. 1998. Phosphorylcholinecoated metallic stents in rabbit iliac and porcine coronary arteries. Scand. Cardiovasc. J. 32:261-68 (Pubitemid 28510636)
144. Malik N, Gunn J, Shepherd L, Crossman DC, Cumberland DC, Holt CM. 2001. Phosphorylcholinecoated stents in porcine coronary arteries: in vivo assessment of biocompatibility. J. Invasive Cardiol. 13:193-201 (Pubitemid 33759145)
145. Zheng H, Barragan P, Corcos T, Simeoni JB, Favereau X, et al. 1999. Clinical experience with a new biocompatible phosphorylcholine-coated coronary stent. J. Invasive Cardiol. 11:608-14
146. L'Heureux N, Dusserre N, Konig G, Victor B, Keire P, et al. 2006. Human tissue-engineered blood vessels for adult arterial revascularization. Nat. Med. 12:361-65 (Pubitemid 43355087)
147. Niklason LE, Gao J, AbbottWM, Hirschi KK, Houser S, et al. 1999. Functional arteries grown in vitro. Science 284:489-93 (Pubitemid 29289622)
148. Weinberg CB, Bell E. 1986. A blood vessel model constructed from collagen and cultured vascular cells. Science 231:397-400 (Pubitemid 16108649)
149. Walluscheck KP, Steinhoff G, Kelm S, Haverich A. 1996. Improved endothelial cell attachment on ePTFE vascular grafts pretreated with synthetic RGD-containing peptides. Eur. J. Vasc. Endovasc. Surg. 12:321-30 (Pubitemid 26379148)
150. Herring M, Smith J, Dalsing M, Glover J, Compton R, et al. 1994. Endothelial seeding of polytetrafluoroethylene femoral popliteal bypasses: the failure of low-density seeding to improve patency. J. Vasc. Surg. 20:650-55 (Pubitemid 24322696)
151. Galbraith CG, Skalak R, Chien S. 1998. Shear stress induces spatial reorganization of the endothelial cell cytoskeleton. Cell Motil. Cytoskelet. 40:317-30 (Pubitemid 28364153)
152. Li S, Kim M, Hu YL, Jalali S, Schlaepfer DD, et al. 1997. Fluid shear stress activation of focal adhesion kinase: linking to mitogen-activated protein kinases. J. Biol. Chem. 272:30455-62 (Pubitemid 27512256)
153. Meinhart JG, Schense JC, Schima H, Gorlitzer M, Hubbell JA, et al. 2005. Enhanced endothelial cell retention on shear-stressed synthetic vascular grafts precoated with RGD-cross-linked fibrin. Tissue Eng. 11:887-95 (Pubitemid 40960791)
154. Baguneid M, Murray D, Salacinski HJ, Fuller B, Hamilton G, et al. 2004. Shear-stress preconditioning and tissue-engineering-based paradigms for generating arterial substitutes. Biotechnol. Appl. Biochem. 39:151-57 (Pubitemid 38510060)
155. OttMJ, BallermannBJ. 1995. Shear stress-conditioned, endothelial cell-seeded vascular grafts: improved cell adherence in response to in vitro shear stress. Surgery 117:334-39
156. Walluscheck KP, Steinhoff G, Kelm S, Haverich A. 1996. Improved endothelial cell attachment on ePTFE vascular grafts pretreated with synthetic RGD-containing peptides. Eur. J. Vasc. Endovasc. Surg. 12:321-30 (Pubitemid 26379148)
157. Pfaff M, Tangemann K, M̈uller B, Gurrath M, M̈uller G, et al. 1994. Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha αIIbβ3, αVβ3, and α5β1 integrins. J. Biol. Chem. 269:20233-38 (Pubitemid 24260416)
158. Jun H-W, West J. 2004. Development of a YIGSR-peptide-modified polyurethaneurea to enhance endothelialization. J. Biomater. Sci. Polym. Ed. 15:73-94 (Pubitemid 38239672)
159. Massia S, Hubbell J. 1992. Vascular endothelial cell adhesion and spreading promoted by the peptide REDV of the IIICS region of plasma fibronectin is mediated by integrinα4β1. J. Biol. Chem. 267:14019-26
160. Hodde J, Record R, Tullius R, Badylak S. 2002. Fibronectin peptides mediate HMEC adhesion to porcine-derived extracellular matrix. Biomaterials 23:1841-48
161. Taite LJ, Yang P, Jun H-W, West JL. 2008. Nitric oxide-releasing polyurethane-PEG copolymer containing the YIGSR peptide promotes endothelialization with decreased platelet adhesion. J. Biomed. Mater. Res. B 84:108-16
162. Zilla P, Bezuidenhout D, Human P. 2007. Prosthetic vascular grafts: wrong models, wrong questions and no healing. Biomaterials 28:5009-27
163. Li S, Bhatia S, Hu YL, Shiu YT, Li YS, et al. 2001. Effects of morphological patterning on endothelial cell migration. Biorheology 38:101-8 (Pubitemid 32573706)
164. Thakar RG, Ho F, Huang NF, Liepmann D, Li S. 2003. Regulation of vascular smooth muscle cells by micropatterning. Biochem. Biophys. Res. Commun. 307:883-90 (Pubitemid 36871656)
165. Uttayarat P, Perets A, Li M, Pimton P, Stachelek SJ, et al. 2010. Micropatterning of three-dimensional electrospun polyurethane vascular grafts. Acta Biomater. 6:4229-37
166. Shen Y, Wang G, Chen L, Li H, Yu P, et al. 2009. Investigation of surface endothelialization on biomedical nitinol (NiTi) alloy: effects of surface micropatterning combined with plasma nanocoatings. Acta Biomater. 5:3593-604
167. Shi Q, Bhattacharya V, Hong-DeWu M, Sauvage LR. 2002. Utilizing granulocyte colony-stimulating factor to enhance vascular graft endothelialization from circulating blood cells. Ann. Vasc. Surg. 16:314-20 (Pubitemid 34761163)
168. Stellos K, Langer H, Daub K, Schoenberger T, Gauss A, et al. 2008. Platelet-derived stromal cell-derived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells. Circulation 117:206-15
169. Hiasa K-i, Ishibashi M, Ohtani K, Inoue S, Zhao Q, et al. 2004. Gene transfer of stromal cell-derived factor-1α enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation 109:2454-61
170. Kalka C, Masuda H, Takahashi T, Gordon R, Tepper O, et al. 2000. Vascular endothelial growth factor165 gene transfer augments circulating endothelial progenitor cells in human subjects. Circ. Res. 86:1198-202 (Pubitemid 30436658)
171. Kalka C, Tehrani H, Laudenberg B, Vale PR, Isner JM, et al. 2000. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. Ann. Thorac. Surg. 70:829-34
172. Szmitko PE, Fedak PWM,Weisel RD, Stewart DJ, Kutryk MJB, Verma S. 2003. Endothelial progenitor cells: new hope for a broken heart. Circulation 107:3093-100 (Pubitemid 36758985)
173. Dimmeler S, Aicher A, VasaM,Mildner-Rihm C, Adler K, et al. 2001. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Investig. 108:391-97 (Pubitemid 32730785)
174. Rotmans JI, Heyligers JMM, Verhagen HJM, Velema E, Nagtegaal MM, et al. 2005. In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts. Circulation 112:12-18 (Pubitemid 40962563)
175. Simper D. 2002. Smooth muscle progenitor cells in human blood. Circulation 106:1199-204 (Pubitemid 34988636)
176. Wendel HP, Avci-Adali M, Ziemer G. 2009. Endothelial progenitor cell capture stents-hype or hope? Int. J. Cardiol. 145:115-17
177. Hoffmann J, Paul A, Harwardt M, Groll J, Reeswinkel T, et al. 2008. Immobilized DNA aptamers used as potent attractors for porcine endothelial precursor cells. J. Biomed. Mater. Res. A 84:614-21 (Pubitemid 351237778)
178. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ. 1992. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355:564-66
179. Brennan MP, Dardik A, Hibino N, Roh JD, Nelson GN, et al. 2008. Tissue-engineered vascular grafts demonstrate evidence of growth and development when implanted in a juvenile animal model. Ann. Surg. 248:370-77
180. Gong Z, Niklason LE. 2008. Small-diameter human vessel wall engineered from bone marrow-derived mesenchymal stem cells (hMSCs). FASEB J. 22:1635-48
181. Hashi CK, Zhu Y, Yang GY, Young WL, Hsiao BS, et al. 2007. Antithrombogenic property of bone marrow mesenchymal stem cells in nanofibrous vascular grafts. Proc. Natl. Acad. Sci. USA 104:11915-20 (Pubitemid 47185605)
182. Huang NF, Li S. 2008. Mesenchymal stem cells for vascular regeneration. Regen. Med. 3:877-92
183. Jackson SP. 2007. The growing complexity of platelet aggregation. Blood 109:5087-95
184. Yamanaka S, Blau HM. 2010. Nuclear reprogramming to a pluripotent state by three approaches. Nature 465:704-12
185. Hanna JH, Saha K, Jaenisch R. 2010. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell 143:508-25